These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31294338)

  • 21. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An overview of the pathfinder clinical trials program: Long-term efficacy and safety of N8-GP in patients with hemophilia A.
    Matsushita T; Mangles S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):26-33. PubMed ID: 32558236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis.
    Chowdary P; Fischer K; Collins PW; Cotterill A; Konkle BA; Blanchette V; Pipe SW; Berntorp E; Wolfsegger M; Engl W; Spotts G
    Thromb Haemost; 2020 May; 120(5):728-736. PubMed ID: 32369844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term safety and efficacy of N8-GP in previously treated pediatric patients with hemophilia A: Final results from pathfinder5.
    Šaulytė Trakymienė S; Economou M; Kenet G; Landorph A; Shen C; Kearney S
    J Thromb Haemost; 2020 Sep; 18 Suppl 1(Suppl 1):15-25. PubMed ID: 32940955
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Ferrada A; Monte-Boquet E; Pérez-Alenda S; Bosch P; Querol-Giner F; Poveda JL
    Thromb Res; 2021 Sep; 205():99-105. PubMed ID: 34293540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa.
    Lissitchkov T; Willemze A; Jan C; Zilberstein M; Katragadda S
    Res Pract Thromb Haemost; 2023 May; 7(4):100176. PubMed ID: 37538505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).
    Djambas Khayat C; Iosava G; Romashevskaya I; Stasyshyn O; Lopez MJ; Pompa MT; Rogosch T; Seifert W
    J Blood Med; 2021; 12():483-495. PubMed ID: 34188580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of N8-GP Activity Using a One-Stage Clotting Assay: A Single-Center Experience.
    Hegemann I; Koch K; Clausen WHO; Ezban M; Brand-Staufer B
    Acta Haematol; 2020; 143(5):504-508. PubMed ID: 31639805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting the outcomes of using longer-acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis.
    Miners AH; Krishnan S; Pasi KJ
    J Thromb Haemost; 2016 Nov; 14(11):2141-2147. PubMed ID: 27510890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
    Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
    J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetic Analysis of Recombinant Factor VIII Fc Fusion Protein in Subjects With Severe Hemophilia A: Expanded to Include Pediatric Subjects.
    Katragadda S; Neelakantan S; Diao L; Wong N
    J Clin Pharmacol; 2021 Jul; 61(7):889-900. PubMed ID: 33719084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
    Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct
    Bjørnsdottir I; Støvring B; Søeborg T; Jacobsen H; Sternebring O
    Drugs R D; 2020 Jun; 20(2):75-82. PubMed ID: 32152818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
    Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.
    Chen Z; Huang K; Li G; Zhen Y; Wu X; Di A; Liu G; Li Z; Alfonso I; Wu R
    Pediatr Investig; 2021 Mar; 5(1):38-45. PubMed ID: 33778426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.